Skip to content
Recovery & autonomic healthEvidence review3 min read

Wearable HRV shifts with the menstrual cycle, contraceptive use and menopause, review finds

MoveVitals Editorial Collective · Study published · Reading updated

Original paper:Wearable-Derived Heart Rate Variability Across the Menstrual Cycle, Hormonal Contraceptive Use, and Reproductive Life Stages in Females: A Living Systematic Review. · Sports medicine (Auckland, N.Z.) · 2026 · Original paper ↗

Key takeaway

Across 16 studies, wearable-measured HRV was higher early in the menstrual cycle and lower toward the end, with time-domain differences of 3 to 9%, and was lower in hormonal contraceptive users. Studies defined cycle phases and menopause differently, so the results could not be pooled statistically.

Study design

Evidence review

Reading basis

Published abstract

Reading focus

Design & applicability

The research question

Wearables now track heart rate variability (HRV, a marker linked to autonomic nervous system function) around the clock, but ovarian hormones may change it in ways that confuse interpretation. The authors reviewed what wearable HRV studies show across the menstrual cycle, hormonal contraceptive use, pregnancy and menopause.

Who and how

Living systematic review. PubMed, Web of Science, IEEE Xplore, SPORTDiscus and Embase were searched from inception to December 2025 using a Participant-Exposure-Outcome framework. Studies were double screened and had to examine wearable-measured HRV across the menstrual cycle in naturally menstruating females, in response to exogenous ovarian hormones, or across another hormonal state such as menopause or pregnancy. Cohort study quality was assessed with the Newcastle-Ottawa Scale. From 299 records, 16 studies were included. Registered on OSF.

What it found

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    In naturally menstruating females, HRV was higher at the beginning of the cycle and lower toward the end, with differences in time-domain HRV ranging from 3 to 9%.
  2. 2
    Hormonal contraceptive users showed lower HRV, particularly in the late cycle.
  3. 3
    HRV tended to decline after menopause with increasing age.
  4. 4
    Evidence quality was moderate (7/9 on the Newcastle-Ottawa Scale). Inconsistent classification of cycle phases and menopausal status limited comparability and prevented a quantitative synthesis.

Limits & uncertainty

  1. 1
    Only 16 studies were included, and differing definitions of cycle phase and menopausal status mean the findings are a qualitative summary without pooled estimates.
  2. 2
    The 3 to 9% range is small relative to day-to-day HRV variation, and the abstract does not say how many participants were involved or which devices were used.
  3. 3
    Age and menopause are entangled, since HRV declines with age anyway, so the menopause finding is hard to separate from ageing.
  4. 4
    This reading is based on the abstract only.

What to take from it

If you track HRV and menstruate, expect a gentle drift across your cycle rather than reading every dip as stress or overtraining. Hormonal contraception may sit at a lower baseline. Questions about symptoms or hormones belong with your clinician.

Reading your own data

Compare your HRV with your own baseline from the same cycle phase, on the same device and at the same time of night, and use multi-week trends rather than single readings. Logging cycle day alongside HRV, sleep and training load can make the pattern easier to see.

How to read this evidence

Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.

Authors’ structured abstract English

The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.

Background

Heart rate variability (HRV) reflects autonomic nervous system function and can now be continuously monitored in real-world settings using wearable technology. However, the influence of ovarian hormones on HRV remains unclear, underscoring the need to synthesize evidence across the female lifespan.

Objective

To examine the association between ovarian hormone profiles and HRV measured by wearable/mobile devices.

Design

Living systematic review.

Data sources

A comprehensive search was conducted in PubMed, Web of Science, IEEE Xplore, SPORTDiscus, and Embase from inception to December 2025. The search followed the Participant (females of any age), Exposure (ovarian hormone profiles), and Outcomes (HRV measured by wearable devices) framework, using a combination of MeSH terms and keyword adaptations. Quality was assessed for cohort studies using the Newcastle-Ottawa Scale.

Eligibility criteria

All studies were independently double screened by title, abstract, and full text. Studies were eligible if they examined differences in HRV measured by a wearable device, across the menstrual cycle in naturally menstruating females, in response to exogenous ovarian hormones, or across another ovarian hormone state such as menopause or pregnancy.

Results

From 299 identified records, 16 studies were included. In naturally menstruating females, HRV was higher at the beginning of the cycle and lower toward the end, with differences in time-domain HRV ranging from 3 to 9%. Hormonal contraceptive users exhibited lower HRV, particularly in the late cycle. Additionally, HRV tended to decline after menopause with increasing age. The quality of evidence in this review was moderate (7/9). Variability in how menstrual cycle phases and menopausal status were classified across studies limited comparability and the ability to synthesize findings quantitatively.

Conclusions

Wearable-derived HRV is associated with differences across the menstrual cycle, oral contraceptive use, and reproductive life stages. This should be considered when presenting HRV metrics to female users. This may improve the interpretation of data for female athletes, patients, or women who track their HRV.

Osf registration

DOI https://doi.org/10.17605/OSF.IO/S4RYW .

Sources & attribution

Wearable-Derived Heart Rate Variability Across the Menstrual Cycle, Hormonal Contraceptive Use, and Reproductive Life Stages in Females: A Living Systematic Review.

de Jager E, Caulfield B, Angelidi E, MacNamee B, Holden S.

Sports medicine (Auckland, N.Z.) · 2026-01-17

DOI: 10.1007/s40279-025-02388-y ↗PubMed · 41545627 ↗Europe PMC · Recorded licence: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

MoveVitals editorial interpretation · educational content · no individual clinical review recorded

Sources checked 2026-11-01

Practical guides

Read in context

·Research article

Short-term HRV was higher during slow breathing in 962 military men, injured or not

In 962 military men (median age 37.6 years), every short-term heart rate variability (HRV) measure was higher during slow breathing at six breaths a minute than during spontaneous breathing, injured or not; in fast resting breathers RMSSD rose from 15.57 to 21.89 ms. It was one session in a fixed order, so it shows an immediate effect, not lasting benefit.

European Journal of Applied Physiology

In-depth explainersRead study →
·Trial meta-analysis

Cold-water immersion: no strength gain, briefly weaker jumps, soreness relief uncertain

Across 22 randomised trials (375 participants, mostly men), one cold-water immersion after exercise did not change maximal isometric strength (g 0.08, 95% CI −0.11 to 0.26) and was followed by weaker jumping straight afterwards (g −0.68), gone by 24–48 hours. Lower soreness and creatine kinase looked favourable but weakened in sensitivity checks, and certainty was low to very low.

PeerJ

In-depth explainersRead study →
·Evidence review

Cold-water immersion after hard exercise: less soreness, better power, no strength gain

In a meta-analysis of 52 randomised trials, cold-water immersion after high-intensity exercise was followed 24 hours later by lower soreness (SMD −0.89), higher perceived recovery (0.66) and better muscular power (0.22), with no effect on strength. Participants could not be blinded, most were men, and many pooled results rest on few studies with high heterogeneity.

Sports Medicine

In-depth explainersRead study →
·Methods & interpretation

Acute:chronic workload ratio: no evidence it can reduce injury risk, authors argue

The authors argue there is no evidence for using the acute:chronic workload ratio (ACWR) in training-load management or to reduce injury risk: no study has properly estimated a causal effect, and the ratio is statistically inaccurate and ambiguous. This is a methodological critique, not a new data analysis, so it does not show that training load is unrelated to injury.

International Journal of Sports Physiology and Performance

In-depth explainersRead study →
Recovery & autonomic health →